Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical SNDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 3.14% | |
| Narrow Range Bar | Range Contraction | 3.14% | |
| NR7 | Range Contraction | 3.14% | |
| NR7-2 | Range Contraction | 3.14% | |
| 20 DMA Resistance | Bearish | 3.14% | |
| Bollinger Band Squeeze | Range Contraction | 3.14% | |
| NR7 | Range Contraction | 3.14% | |
| 20 DMA Resistance | Bearish | 3.14% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2019
- Sector: Healthcare
- Industry: Biotechnology
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Lung Cancer Pyridines Hematological Malignancies Late Stage Biopharmaceutical Benzamides Carbamates National Cancer Institute
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Lung Cancer Pyridines Hematological Malignancies Late Stage Biopharmaceutical Benzamides Carbamates National Cancer Institute
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more SNDX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 9.37 |
| 52 Week Low | 3.39 |
| Average Volume | 197,648 |
| 200-Day Moving Average | 6.1213 |
| 50-Day Moving Average | 6.4046 |
| 20-Day Moving Average | 7.3985 |
| 10-Day Moving Average | 7.404 |
| Average True Range | 0.4451 |
| ADX | 21.33 |
| +DI | 24.5173 |
| -DI | 17.8888 |
| Chandelier Exit (Long, 3 ATRs ) | 6.694699999999999 |
| Chandelier Exit (Short, 3 ATRs ) | 8.0153 |
| Upper Bollinger Band | 7.8893 |
| Lower Bollinger Band | 6.9077 |
| Percent B (%b) | 0.65 |
| BandWidth | 13.267554 |
| MACD Line | 0.2374 |
| MACD Signal Line | 0.3078 |
| MACD Histogram | -0.0704 |
| Fundamentals | Value |
|---|---|
| Market Cap | 167.75 Million |
| Num Shares | 22.2 Million |
| EPS | -2.84 |
| Price-to-Earnings (P/E) Ratio | -2.66 |
| Price-to-Sales | 191.23 |
| Price-to-Book | 2.13 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.14 | ||||
| Resistance 3 (R3) | 8.12 | 7.91 | 8.04 | ||
| Resistance 2 (R2) | 7.91 | 7.76 | 7.92 | 8.00 | |
| Resistance 1 (R1) | 7.73 | 7.67 | 7.82 | 7.75 | 7.97 |
| Pivot Point | 7.52 | 7.52 | 7.57 | 7.53 | 7.52 |
| Support 1 (S1) | 7.34 | 7.37 | 7.43 | 7.36 | 7.13 |
| Support 2 (S2) | 7.13 | 7.28 | 7.14 | 7.10 | |
| Support 3 (S3) | 6.95 | 7.13 | 7.06 | ||
| Support 4 (S4) | 6.97 |
